Escient is a clinical-stage pharmaceutical company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory diseases. Our pipeline includes two first-in-class small molecule antagonists targeting MRGPRX2 for the treatment of various mast cell-mediated disorders and MRGPRX4 for cholestatic pruritus. Based in San Diego, California, Escient is led by an experienced team with specific expertise in GPCR drug discovery and development and funded by top-tier life science investors.